Archive · 1 Jan 2026
Caplin Point Acquires 10 ANDAs for US Market
Caplin Point Laboratories, a big medicine-making company, has bought 10 special approvals for making medicines that are injected or used in the eyes.
These medicines are sold in the United States and will also be sold in other countries like Mexico, Canada, and Brazil.
The company's boss said this is a big step for their growth, especially in the US.
They also have a special place just for making cancer medicines.
The company mostly sells medicines in places like Latin America and Africa.
Caplin Point Laboratories acquired 10 approved ANDAs for injectable and ophthalmic products.
The addressable market for these products is valued at $473.2 million for the 12-month period ending August 2025.
The acquisition strengthens Caplin's portfolio in the US market and includes select oncology injectables.
The company plans to extend these products to key non-US markets including Mexico, Canada, the European Union, and Brazil.
Caplin Point Laboratories focuses on emerging markets in Latin America and Africa.
- Who
- Caplin Point Laboratories Limited, through its subsidiaries Caplin Steriles Limited and Caplin One Labs Limited
- What
- Acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products
- When
- Announced on January 1, 2026
- Where
- United States, with plans to extend to Mexico, Canada, European Union, and Brazil
- Why
- To strengthen and expand its portfolio in the US market and beyond
- Company
- Caplin Point Laboratories Limited
- Subsidiaries Involved
- Caplin Steriles Limited, Caplin One Labs Limited
- Acquisition Type
- 10 approved ANDAs
- Market Segment
- Injectables and ophthalmic products
- Market Value
- $473.2 million (12-month period ending August 2025)
- Key Markets
- United States, Mexico, Canada, European Union, Brazil
- Specialty Facility
- Dedicated oncology facility in Kakkalur
- Company Focus
- Emerging markets of Latin America and Africa